Pembrolizumab shows promise for relapsed/refractory PMBCLOctober 24, 2019Lymphoma & Plasma Cell DisordersImmuno-oncology
Immunotherapy enables nephrectomy with good outcomes in advanced RCCOctober 21, 2019Renal Cell CarcinomaGenitourinary CancerImmuno-oncology
Nivolumab boosts overall survival in HCCOctober 14, 2019GastroenterologyImmuno-oncologyGastrointestinal Cancer
Atezolizumab plus chemo gives slight PFS edge in mUCOctober 8, 2019Genitourinary CancerImmuno-oncology
Nivolumab-ipilimumab nets long-term survival in advanced melanomaOctober 5, 2019MelanomaImmuno-oncology
No difference between ipilimumab/nivolumab combo and immunotherapy plus VEGF for metastatic RCCOctober 2, 2019Renal Cell CarcinomaImmuno-oncologyGenitourinary Cancer
Immunotherapies under investigation in newly diagnosed B-ALLOctober 1, 2019Leukemia, Myelodysplasia, TransplantationImmunotherapyImmuno-oncology
OS benefit with pembrolizumab endures long-term in advanced NSCLCSeptember 24, 2019Lung CancerImmuno-oncology
CT103A elicits responses after prior CAR T-cell relapseSeptember 19, 2019Lymphoma & Plasma Cell DisordersImmuno-oncology
Cancer patients increasingly being discharged to subacute rehabilitation facilitiesSeptember 12, 2019Practice ManagementImmuno-oncologyPatient & Survivor Care
Prior antibiotic use lowers checkpoint inhibitor response and survivalSeptember 12, 2019Immuno-oncologyLung CancerPatient & Survivor CareMelanoma
Nivolumab falls short in ccRCC patients with brain metastasesAugust 28, 2019Renal Cell CarcinomaImmunotherapyImmuno-oncology
Nivolumab yields long-term survival benefit in advanced NSCLCAugust 26, 2019Lung CancerImmuno-oncology
Pretreatment CT data may help predict immunotherapy benefit in ovarian cancerAugust 26, 2019Immuno-oncologyGynecologic CancerImmunotherapy
Immune-related toxicities, hospitalization common with checkpoint inhibitor therapyAugust 12, 2019Lung CancerImmuno-oncologyHead & Neck/Thyroid Cancers
